Syena secures exclusive license to Miltenyi Biotec’s PRAME TCR Syena, co-founded by Replay and MD Anderson in 2023, will develop an off-the-shelf PRAME TCR-NK cell therapy, with IND anticipated Q1 ...
Making autologous cell therapies is a logistical challenge as much as a technical one. Material from the hospitalized patient must be transferred to a facility for processing before being returned for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback